For selected patients, semaglutide has also become part of the cardiovascular-risk conversation because Wegovy has an FDA-approved indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Quick GLP-1 Review First, let's quickly review what these medicines are
[25] noted that patients on GLP-1 RAs experienced modest systolic BP reductions in parallel with reductions in body mass index (BMI) and hemoglobin A1c, suggesting the BP effect is secondary to improvements in weight and metabolic control
To further examine the possibility that MK-801 could convey protraction, we synthesized a series of conjugates comprising MK-801 in combination with other peptide analogues, peptide YY (PYY), glucose insulinotropic peptide (GIP) as well as a GIP/GLP-1 co-agonist, for which half-life extension has been shown to enhance weight loss efficacy 23,24,25,26